Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Pfizer – Recall of Chantix® (varenicline) to warehouse level

The FDA announced a voluntary, warehouse-level recall of nine lots of Pfizer’s Chantix (varenicline) tablets because they may contain levels of a nitrosamine impurity, called N-nitroso-varenicline, above FDA’s acceptable intake limit. July 2, 2021

Actemra® (tocilizumab) – Emergency use authorization approval

The FDA announced the emergency use authorization (EUA) approval of Genentech’s Actemra (tocilizumab), for the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. June 24, 2021

Verkazia® (cyclosporine) – New orphan drug approval

Santen Pharmaceutical announced the FDA approval of Verkazia (cyclosporine) ophthalmic emulsion 0.1%, for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. June 24, 2021

Perforomist® (formoterol fumarate) – First-time generic

Teva launched an AN-rated generic version of Mylan Specialty’s Perforomist (formoterol fumarate) inhalation solution. June 22, 2021

Toviaz® (fesoterodine fumarate) – New indication

The FDA approved Pfizer’s Toviaz (fesoterodine fumarate), for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg. June 17, 2021

Grifols – Withdrawal of Gamunex-C® (immune globulin [human])

Grifols Therapeutics announced a voluntary, consumer-level withdrawal of one lot of Gamunex-C (immune globulin [human]) injection due to a higher rate of allergic/hypersensitivity type reactions, a small number of which were considered medically significant. June 25, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.